Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences

International Journal of Clinical and Experimental Medicine

Volumn 6, Issue 2, 2013, Pages 110-118

  Amit, Doron ^a   Tamir, Sagi ^a   Hochberg, Abraham ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Glioblastoma; HCC; IGF2; Ovarian cancer; Pancreatic cancer; Targeted cancer therapy

Indexed keywords

DIPHTHERIA TOXIN; SOMATOMEDIN B RECEPTOR;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; DNA SYNTHESIS; DOSE RESPONSE; EXPRESSION VECTOR; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; OVARY CANCER; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN SYNTHESIS INHIBITION; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA ISOLATION; SOLID TUMOR;

EID: 84873102688     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Chao W and D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008; 19: 111-120.
2. LeRoith D and Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137.
3. Pavelic K, Bukovic D and Pavelic J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 2002; 8: 771-780.
4. Samani AA, Yakar S, LeRoith D and Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
5. Yu H and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
6. Engstrom W, Shokrai A, Otte K, Granerus M, Gessbo A, Bierke P, Madej A, Sjolund M and Ward A. Transcriptional regulation and biological signifcance of the insulin like growth factor II gene. Cell Prolif 1998; 31: 173-189.
7. de Pagter-Holthuizen P, Jansen M, van Schaik FM, van der Kammen R, Oosterwijk C, Van den Brande JL and Sussenbach JS. The human insulin-like growth factor II gene contains two development-specifc promoters. FEBS Lett 1987; 214: 259-264.
8. Amit D, Tamir S, Birman T, Gofrit ON and Hoch-berg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences. Int J Clin Exp Med 2011; 4: 91-102.
9. Foulstone E, Prince S, Zaccheo O, Burns JL, Harper J, Jacobs C, Church D and Hassan AB. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 2005; 205: 145-153.
10. Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR and Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006; 4: 283-292.
11. Reeve AE, Eccles MR, Wilkins RJ, Bell GI and Millow LJ. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 1985 Sep 19-25; 317: 258-60.
12. Scott J, Cowell J, Robertson ME, Priestley LM, Wadey R, Hopkins B, Pritchard J, Bell GI, Rall LB, Graham CF and et al. Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues. Nature 1985; 317: 260-262.
13. Cariani E, Lasserre C, Seurin D, Hamelin B, Ke-meny F, Franco D, Czech MP, Ullrich A and Brechot C. Differential expression of insulinlike growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988 Dec 1; 48: 6844-9.
14. Cariani E, Seurin D, Lasserre C, Franco D, Bin-oux M and Brechot C. Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis. J Hepatol 1990; 11: 226-231.
15. Fichera E, Liang S, Xu Z, Guo N, Mineo R and Fujita-Yamaguchi Y. A quantitative reverse transcription and polymerase chain reaction assay for human IGF-II allows direct comparison of IGF-II mRNA levels in cancerous breast, bladder, and prostate tissues. Growth Horm IGF Res 2000 Apr; 10: 61-70.
16. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S and Fujita-Yamaguchi Y. Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res 1998 Mar; 291: 469-79.
17. Hassan AB and Howell JA. Insulin-like growth factor II supply modifes growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 2000; 60: 1070-1076.
18. Tricoli JV, Rall LB, Karakousis CP, Herrera L, Pe-trelli NJ, Bell GI and Shows TB. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986; 46: 6169-6173.
19. Wang S, Souza RF, Kong D, Yin J, Smolinski KN, Zou TT, Frank T, Young J, Flanders KC, Sugimu-ra H, Abraham JM and Meltzer SJ. Defcient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IG-FII) expression in IGFII receptor-mutant tumors. Cancer Res 1997; 57: 2543-2546.
20. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F and Le Bouc Y. Rearrangements at the 11p15 locus and over-expression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endo-crinol Metab 1994; 78: 1444-1453.
21. Liu J, Kahri AI, Heikkila P, Ilvesmaki V and Voutilainen R. H19 and insulin-like growth fac-tor-II gene expression in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 1995; 80: 492-496.
22. Moorehead RA, Sanchez OH, Baldwin RM and Khokha R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 2003; 22: 853-857.
23. Takanami I, Imamuma T, Hashizume T, Kikuchi K, Yamamoto Y, Yamamoto T and Kodaira S. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 1996; 61: 205-208.
24. Nonomura N, Nishimura K, Miki T, Kanno N, Kojima Y, Yokoyama M and Okuyama A. Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. Cancer Res 1997; 57: 2575-2577.
25. Sayer RA, Lancaster JM, Pittman J, Gray J, Whitaker R, Marks JR and Berchuck A. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 2005; 96: 355-361.
26. Lambert S, Carlisi A, Collette J, Franchimont P and Gol-Winkler R. Insulin-like growth factor II in two human colon-carcinoma cell lines: gene structure and expression, and protein secretion. Int J Cancer 1992; 52: 404-408.
27. Lamonerie T, Lavialle C, de Galle B, Binoux M and Brison O. Constitutive or inducible overex-pression of the IGF-2 gene in cells of a human colon carcinoma cell line. Exp Cell Res 1995; 216: 342-351.
28. Schneid H, Holthuizen PE and Sussenbach JS. Differential promoter activation in two human insulin-like growth factor-II-producing tumor cell lines. Endocrinology 1993; 132: 1145-1150.
29. Singh P, Dai B, Given RL, Lu X and Holthuizen PE. Differential activation of IGF-II promoters P3 and P4 in Caco-2 cells during growth and differentiation. Gastroenterology 1998; 114: 1221-1229.
30. Toretsky JA and Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996; 149: 367-372.
31. Werner H and LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68: 183-223.
32. Amit D and Hochberg A. Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of H19 and IGF2-P4 regulatory sequences. J Transl Med 2010; 8: 134.
33. Amit D, Matouk IJ, Lavon I, Birman T, Galula J, Abu-Lail R, Schneider T, Siegal T, Hochberg A and Fellig Y. Transcriptional targeting of glio-blastoma by diphtheria toxin-A driven by both H19 and IGF2-P4 promoters. Int J Clin Exp Med 2012; 5: 124-135.
34. Ayesh B, Matouk I, Ohana P, Sughayer MA, Bir-man T, Ayesh S, Schneider T, de Groot N and Hochberg A. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003 Apr; 7: 535-41.
35. Moschos SJ and Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002; 63: 317-332.
36. Frostad S and Bruserud O. In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. Eur J Haematol 1999; 62: 191-198.
37. LeRoith D, Baserga R, Helman L and Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-59.
38. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-320.
39. Oku K, Tanaka A, Yamanishi H, Nishizawa Y, Matsumoto K, Shiozaki H and Mori T. Effects of various growth factors on growth of a cloned human esophageal squamous cancer cell line in a protein-free medium. Anticancer Res 1991; 11: 1591-1595.
40. Singh P, Dai B, Yallampalli U, Lu X and Schroy PC. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with signifcant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology 1996; 137: 1764-1774.
41. Yaginuma Y, Nishiwaki K, Kitamura S, Hayashi H, Sengoku K and Ishikawa M. Relaxation of insulin-like growth factor-II gene imprinting in human gynecologic tumors. Oncology 1997; 54: 502-507.
42. Morison IM and Reeve AE. Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications. Mol Med Today 1998; 4: 110-115.
43. Ohlsson R and Franklin G. Normal development and neoplasia: the imprinting connection. Int J Dev Biol 1995; 39: 869-876.
44. Wu HK, Squire JA, Catzavelos CG and Weksberg R. Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. Biochem Biophys Res Commun 1997; 235: 123-129.
45. Bae SK, Bae MH, Ahn MY, Son MJ, Lee YM, Bae MK, Lee OH, Park BC and Kim KW. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res 1999; 59: 5989-5994.
46. Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Schwartz P and Yu H. Pro-moter-specifc transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecol Oncol 2006; 103: 990-995.
47. Mineo R, Fichera E, Liang SJ and Fujita-Yama-guchi Y. Promoter usage for insulin-like growth factor-II in cancerous and benign human breast, prostate, and bladder tissues, and con-frmation of a 10th exon. Biochem Biophys Res Commun 2000; 268: 886-892.
48. Sohda T, Yun K, Iwata K, Soejima H and Oku-mura M. Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996; 75: 307-311.
49. Iizuka N, Oka M, Tamesa T, Hamamoto Y and Yamada-Okabe H. Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma. Anticancer Res 2004; 24: 4085-4089.
50. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L, Croce CM, Bar-banti-Brodano G and Negrini M. Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identifed in human hepatocarcinomas. Proc Natl Acad Sci U S A 2000; 97: 5445-5449.
51. Thorgeirsson SS and Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
52. Kim KS and Lee YI. Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma. Cancer Lett 1997; 119: 143-148.
53. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bon-dy ML and Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. Jama 2009; 301: 2553-2562.
54. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbru-zzese JL and Li D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiol 2011; 36: 206-211.
55. Lopez T and Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002; 1: 339-353.
56. Kim HT, Choi BH, Niikawa N, Lee TS and Chang SI. Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am J Med Genet 1998; 80: 391-395.
57. Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO and Hor-witz SB. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res 2010; 16: 2999-3010.
58. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A and Galun E. The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2007; 2: e845.
59. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T and Hoffman AR. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003; 111: 265-273.
60. Biran H, Ariel I, de Groot N, Shani A and Hoch-berg A. Human imprinted genes as oncodevel-opmental markers. Tumour Biol 1994; 15: 123-134.
61. Maxwell IH, Glode LM and Maxwell F. Expression of diphtheria toxin A-chain in mature B-cells: a potential approach to therapy of B-lym-phoid malignancy. Leuk Lymphoma 1992; 7: 457-462.
62. Kawamoto K, Onodera H, Kan S, Kondo S and Imamura M. Possible paracrine mechanism of insulin-like growth factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 1999; 85: 18-25.